Altre lingue Aptose Biosciences Inc.

Azioni

APS

CA03835T3091

Tempo differito Toronto S.E. Altri mercati azionari 18:23:54 24/05/2024			Variaz. 5gg	Var. 1 gen.
1,57 ^CAD	+6,80%		-2,48%	-53,13%

14/05	Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Perdita netta Q1 di Aptose Biosciences in calo, grazie alla riduzione delle spese	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

APTE BIOS : Earnings Presentation	15/05
APTE BIOS : Aptose 1Q Earnings Presentation	14/05
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses	14/05
Aptose Biosciences: Q1 Earnings Snapshot	14/05
Aptose Biosciences Brief: Also Notes TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML	14/05
Aptose Biosciences Brief: Notes TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to FDA During Q1 and is Now Being Activated at Clinical Sites	14/05
Aptose Biosciences Brief: Q1 Net Loss per share, Basic and diluted US$(0.73)	14/05
Aptose Reports Results for the First Quarter 2024	14/05
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024	06/05
APTE BIOS : Aptose Corporate Presentation May 2024	03/05
APTE BIOS : Material Agreement - Form 8-K	26/04
Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
APTE BIOS : Aptose Corporate Presentation April 2024	24/04
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending	26/03
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"	26/03
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"	26/03
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58	26/03
Aptose Reports Results for the Fourth Quarter and Full Year 2023	26/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aptose Biosciences Inc.

Azioni

APS

CA03835T3091

Altre lingue

Filtri